Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis

Affiliations

• ¹ Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
• ² Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
• ³ Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
• ⁴ Veterans Affairs Medical Center and University of Minnesota, Minneapolis, Minnesota, USA.
• ⁵ British Heart Foundation Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom.
• ⁶ National Heart Centre Singapore and Duke-National University of Singapore, Singapore.
• ⁷ Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
• ⁸ Université de Lorraine, Inserm Clinical Investigation Centre, CHU, Nancy, France.
• ⁹ Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South Carolina, USA.
• ¹⁰ Bayer Pharmaceuticals, Research & Development, Wuppertal, Germany.
• ¹¹ Bayer Pharmaceuticals PLC, Research & Development, Reading, United Kingdom.
• ¹² Bayer Pharmaceuticals, Research & Development, Whippany, New Jersey, USA.
• ¹³ Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address: mvaduganathan@bwh.harvard.edu.